Catalyst Wire Dossier Catalyst Wire Dossier

MF59-adjuvanted quadrivalent influenza vaccine

· Seqirus
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MF59-adjuvanted quadrivalent influenza vaccine, covering 2020-06-09 to 2020-06-09. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age [Phase 3]

See pricing